{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:05:11Z","timestamp":1756811111045,"version":"3.40.3"},"reference-count":11,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"\nBackground<\/jats:title>\nAlopecia areata (AA) is a chronic autoimmune dermatosis with significant challenges in the treatment of severe cases. Recently, tofacitinib has been a promising cure for moderate to severe AA. Yet, its long-term efficacy and safety in the treatment of alopecia totalis (AT) and alopecia universalis (AU) remain underexplored, and determinants of its effectiveness are poorly understood.<\/jats:p>\n<\/jats:sec>\n\nAim<\/jats:title>\nTo evaluate the long-term efficacy and safety of tofacitinib in AT and AU patients and explore the factors that may influence treatment outcomes.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nWe retrospectively assessed the efficacy and safety of tofacitinib in 69 AT and AU patients between January 2020 and June 2024. We also explored risk factors affecting the efficacy of tofacitinib using binary logistic regression analysis.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nAfter a median treatment of 6 months with tofacitinib, 47.8% (33\/69) of patients had a severity of alopecia tool (SALT) score \u2264 20, and 26.1% (18\/69) had complete hair regrowth. Patients showed more pronounced SALT score reductions and significant efficacy at weeks 24 and 36, compared to week 12 (P < 0.01). Binary logistic regression analysis revealed that younger initial age of AA (odds ratio (OR) = 1.063, 95% confidence interval (CI) 1.011-1.117, P = 0.017) and shorter treatment duration (OR = 1.249, 95% CI 1.065-1.465, P = 0.006) were significant risk factors associated with poorer efficacy of tofacitinib. Acneiform rash and folliculitis were the primary adverse effects.<\/jats:p>\n<\/jats:sec>\n\nLimitation<\/jats:title>\nThe single-center, retrospective study may be limited by data deficiencies and a small sample size.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nTofacitinib demonstrated significant efficacy in treating patients with AT and AU within a minimum of 6 months. Severe adverse reactions were not observed. Notably, the age of AA onset and the duration of tofacitinib treatment may be significant factors influencing its therapeutic outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_1755_2024","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T09:34:58Z","timestamp":1742981698000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients"],"prefix":"10.25259","volume":"0","author":[{"given":"Wenjun","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuying","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Capital Medical University Affiliated Beijing Hospital of Traditional Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, China-Japan Friendship Hospital, National Center for Integrated Traditional Chinese and Western Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingquan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, China-Japan Friendship Hospital, National Center for Integrated Traditional Chinese and Western Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"10.25259\/IJDVL_1755_2024\/ref-1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-Sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-3","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-5","doi-asserted-by":"publisher","first-page":"891434","DOI":"10.3389\/fmed.2022.891434","article-title":"Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-Severe alopecia areata: A retrospective study","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.25259\/IJDVL_1755_2024\/ref-6","first-page":"440","article-title":"Alopecia areata investigational assessment guidelines--Part II","volume":"51","author":"Olsen","year":"2004","journal-title":"National alopecia areata foundation. J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2340\/00015555-3057","article-title":"Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: A retrospective study","volume":"99","author":"Shin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-8","doi-asserted-by":"publisher","first-page":"adv13475","DOI":"10.2340\/actadv.v103.13475","article-title":"Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: A retrospective study","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ced\/llae150","article-title":"Efficacy of tofacitinib as an induction agent in severe alopecia areata compared with oral betamethasone weekly pulse","volume":"49","author":"Ahuja","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: Insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1755_2024\/ref-11","doi-asserted-by":"publisher","first-page":"CD013719","DOI":"10.1002\/14651858.CD013719.pub2","article-title":"Treatments for alopecia areata: A network meta-analysis","volume":"10","author":"Mateos-Haro","year":"2023","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-tofacitinib-in-patients-with-total-and-universal-alopecia-a-retrospective-evaluation-of-69-patients\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-tofacitinib-in-patients-with-total-and-universal-alopecia-a-retrospective-evaluation-of-69-patients\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T09:35:00Z","timestamp":1742981700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/efficacy-and-safety-of-tofacitinib-in-patients-with-total-and-universal-alopecia-a-retrospective-evaluation-of-69-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":11,"alternative-id":["10.25259\/IJDVL_1755_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1755_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"article-number":"1"}}